ZHILA YADOLLAHI: Open Payments
NPI 1356916878 · MISSION HILLS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,341 in 61 payments from 17 companies in 2025. Trend: 2023 $433 · 2024 $631 · 2025 $1,341
Food & beverage: $1,341
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $227 |
| Novartis Pharmaceuticals Corporation | 11 | $207 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 11 | $169 |
| Amgen Inc. | 7 | $154 |
| Aurinia Pharma U.S., Inc. | 5 | $101 |
| Travere Therapeutics, Inc. | 3 | $69 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $55 |
| Novo Nordisk Inc | 2 | $52 |
| Calliditas Therapeutics US Inc. | 2 | $51 |
| Otsuka America Pharmaceutical, Inc. | 3 | $50 |
Products named: JARDIANCE, FARXIGA, LOKELMA, LUPKYNIS, KRYSTEXXA, TAVNEOS, Kerendia, Ozempic.
Industry payments across CA — which companies pay providers there.
